These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 30387865

  • 1. Effects of Conversion From Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplant Recipients.
    Tsai KF, Li LC, Hsu CN, Lin CC, Lin YH, Cheng YF, Wang CC, Chen CL.
    J Clin Pharmacol; 2019 Mar; 59(3):326-334. PubMed ID: 30387865
    [Abstract] [Full Text] [Related]

  • 2. Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients.
    Alpay N, Ozkok A, Caliskan Y, Akagun T, Cinar SA, Deniz G, Sariyar M, Yildiz A.
    Clin Exp Nephrol; 2014 Dec; 18(6):961-7. PubMed ID: 24515306
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [Abstract] [Full Text] [Related]

  • 6. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.
    Arora S, Gude E, Sigurdardottir V, Mortensen SA, Eiskjær H, Riise G, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Aukrust P, Solbu D, Iversen M, Gullestad L.
    J Heart Lung Transplant; 2012 Mar; 31(3):259-65. PubMed ID: 22333403
    [Abstract] [Full Text] [Related]

  • 7. Neutrophil gelatinase-associated lipocalin (NGAL) in heart transplant recipients after conversion to everolimus therapy.
    Stypmann J, Fobker M, Rosing K, Engelen M, Gunia S, Dell'Aquila AM, Nofer JR.
    J Cardiol; 2015 Oct; 66(4):347-52. PubMed ID: 25583090
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Renal recovery after conversion to an everolimus-based immunosuppression in early and late heart transplant recipients: a 12-month analysis.
    Michel S, Bigdeli AK, Hagl C, Meiser B, Kaczmarek I.
    Exp Clin Transplant; 2013 Oct; 11(5):429-34. PubMed ID: 24128136
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical Experience of Late Conversion From Antimetabolites With Standard Exposure Calcineurin Inhibitors to Everolimus With Calcineurin Inhibitor Minimization in Stable Kidney Transplant Recipients With Good Renal Function.
    Uchida J, Iwai T, Kuwabara N, Kabei K, Nishide S, Yamasaki T, Naganuma T, Kumada N, Takemoto Y, Nakatanti T.
    Transplant Proc; 2016 Apr; 48(3):775-80. PubMed ID: 27234734
    [Abstract] [Full Text] [Related]

  • 12. Predictors of long-term renal function after conversion to proliferation signal inhibitors in long-term heart transplant recipients.
    González-Vilchez F, de Prada JA, Castrillo C, Canteli A, Llano MF, Martín-Durán R.
    J Heart Lung Transplant; 2011 May; 30(5):552-7. PubMed ID: 21212001
    [Abstract] [Full Text] [Related]

  • 13. Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors.
    Villamil FG, Gadano AC, Zingale F, Perez R, Gil O, Yantorno S, Mastai R, Cairo FO, Otero AB, Dong G, Lopez P, REVERT Study Group.
    Liver Int; 2014 Nov; 34(10):1513-21. PubMed ID: 25453134
    [Abstract] [Full Text] [Related]

  • 14. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J.
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [Abstract] [Full Text] [Related]

  • 15. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
    Hüsing A, Schmidt M, Beckebaum S, Cicinnati VR, Koch R, Thölking G, Stella J, Heinzow H, Schmidt HH, Kabar I.
    Ann Transplant; 2015 Nov 26; 20():707-13. PubMed ID: 26608590
    [Abstract] [Full Text] [Related]

  • 16. Treatment with everolimus is associated with a procoagulant state.
    Baas MC, Gerdes VE, Ten Berge IJ, Heutinck KM, Florquin S, Meijers JC, Bemelman FJ.
    Thromb Res; 2013 Aug 26; 132(2):307-11. PubMed ID: 23906938
    [Abstract] [Full Text] [Related]

  • 17. Long-term outcome of conversion to sirolimus monotherapy after liver transplant.
    Uhlmann D, Weber T, Ludwig S, Ludwig B, Bartels M, Hauss J, Jonas S, Witzigmann H.
    Exp Clin Transplant; 2012 Feb 26; 10(1):30-8. PubMed ID: 22309417
    [Abstract] [Full Text] [Related]

  • 18. Everolimus and long-term decline in renal function after liver transplantation: real-life experience with measured GFR.
    Åberg F, Berntsson J, Herlenius G, Castedal M, Bennet W.
    Scand J Gastroenterol; 2020 Jun 26; 55(6):718-724. PubMed ID: 32479116
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study.
    Albano L, Alamartine E, Toupance O, Moulin B, Merville P, Rerolle JP, Tetaz R, Moal MC, Kamar N, Legendre C, Quéré S, Di Giambattista F, Terpereau A, Dantal J.
    Ann Transplant; 2012 Jun 26; 17(1):58-67. PubMed ID: 22466910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.